Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 7Dermatologic 3Plasma cell 2Myeloid 2Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Leukemia, Myeloid, Chronic-Phase 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Blast Crisis 10Leukemia 7Leukemia, Myeloid, Accelerated Phase 6Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Recurrence 2Primary Myelofibrosis 2Polycythemia Vera 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Cyclophosphamide 67fludarabine phosphate 62Peripheral Blood Stem Cell Transplantation 51Mycophenolic Acid 44Cyclosporine 39Whole-Body Irradiation 38Antilymphocyte Serum 37Tacrolimus 36Busulfan 35Filgrastim 32Radiotherapy 29Methotrexate 23Methylprednisolone 22Melphalan 22Cord Blood Stem Cell Transplantation 21fludarabine 13Etoposide 12Psychiatric Rehabilitation 10Flow Cytometry 10Therapeutics 9Sirolimus 9Granulocyte Colony-Stimulating Factor 8Cytarabine 8Thiotepa 7Alemtuzumab 7Polymerase Chain Reaction 6thymoglobulin 5sargramostim 5Prednisone 5Cyclosporins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Dasatinib × Myeloid × Clear all
NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Dana-Farber Cancer Institute

Phase 1 Recruiting
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡